Immunocore Open menu For patients and families Addressing unmet needs with compassion Home / For patients Our Expanded Access Policy Immunocore is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. Show more At Immunocore, we lead with science to benefit patients. Our aim is to deliver first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, including cancer, infectious diseases and autoimmune diseases. Our approach The ImmTAX™ (Immune Mobilizing Monoclonal T Cell Receptors Against X Disease) platform is aimed at generating a new class of immunotherapy that is designed to overcome the limitations of other immunology agents by combining; a T cell receptor (TCR) to target and recognize the cancerous, infected or autoimmune cells and; an effector function to activate (for cancer and infectious diseases) or suppress (for autoimmune diseases) the immune system. Clinical trials information Clinical trials are an important part of helping to bring safe and effective medicines to patients. All drugs go through a rigorous series of trials, and based on the results, regulatory agencies including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) decide whether to approve medicines. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease. Clinical trials are also an opportunity to be a part of testing a potential new drug. Patients should contact their doctor for information regarding any aspect of their treatment or involvement in clinical trials. We have a number of clinical trials currently recruiting patients: A Phase 1b/2 Study Of The Combination Of IMCgp100 With Durvalumab And/Or Tremelimumab In Cutaneous Melanoma (NCT02535078) Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors, for the treatment of cancers positive for the tumor-associated antigen PRAME (NCT04262466) Safety and Efficacy of IMC-C103C as Monotherapy and in Combination with Atezolizumab for the treatment of cancers positive for tumor-associated antigen MAGE-A4 (NCT03973333) Further information Patients should contact their doctor for information regarding any aspect of their treatment or involvement in clinical trials. For more information on clinical trials visit the clinicaltrials.gov website. clinicaltrials.gov Medical professionals If you are a medical professional and require further information about Immunocore, our clinical research or clinical trials, please email us. Email Immunocore RELATED Our Therapy Areas Pipeline Immunocore About us Our science Our therapy areas For patients Investors/Media Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials Gender Pay Report ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept